Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;24(12):779-786.
doi: 10.1038/gt.2017.90. Epub 2017 Dec 7.

Site-directed RNA editing by adenosine deaminase acting on RNA for correction of the genetic code in gene therapy

Affiliations

Site-directed RNA editing by adenosine deaminase acting on RNA for correction of the genetic code in gene therapy

Md T A Azad et al. Gene Ther. 2017 Dec.

Abstract

Site-directed RNA editing is an important technique for correcting gene sequences and ultimately tuning protein function. In this study, we engineered the deaminase domain of adenosine deaminase acting on RNA (ADAR1) and the MS2 system to target-specific adenosines, with the goal of correcting G-to-A mutations at the RNA level. For this purpose, the ADAR1 deaminase domain was fused downstream of the RNA-binding protein MS2, which has affinity for the MS2 RNA. To direct editing to specific targets, we designed guide RNAs complementary to target RNAs. The guide RNAs directed the ADAR1 deaminase to the desired editing site, where it converted adenosine to inosine. To provide proof of principle, we used an allele of enhanced green fluorescent protein (EGFP) bearing a mutation at the 58th amino acid (TGG), encoding Trp, into an amber (TAG) or ochre (TAA) stop codon. In HEK-293 cells, our system could convert stop codons to read-through codons, thereby turning on fluorescence. We confirmed the specificity of editing at the DNA level by restriction fragment length polymorphism analysis and sequencing, and at the protein level by western blotting. The editing efficiency of this enzyme system was ~5%. We believe that this system could be used to treat genetic diseases resulting from G-to-A point mutations.

PubMed Disclaimer

References

    1. Clin Cancer Res. 2016 Jun 1;22(11):2734-43 - PubMed
    1. Annu Rev Biochem. 2010;79:321-49 - PubMed
    1. Chem Biol Drug Des. 2015 Nov;86(5):1242-52 - PubMed
    1. Nat Commun. 2011;2:319 - PubMed
    1. Chem Biol Drug Des. 2016 Apr;87(4):583-93 - PubMed

Publication types